Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep

M. W. Lightowlers, O. Jensen, E. Fernandez, J. A. Iriarte, D. J. Woollard, C. G. Gauci, D. J. Jenkins, D. D. Heath

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Experimental vaccine trials against hydatid disease have been undertaken in sheep using the EG95 recombinant vaccine. Challenge infection was with viable Echinococcus granulosus eggs obtained from a New Zealand isolate (dog/sheep cycle), an Australian isolate (dingo/wallaby cycle) and an Argentine isolate (dog/sheep cycle). Vaccination with EG95 conferred a high degree of protection against challenge with all three parasite isolates (protection range 96-100%). Taken together, the trials demonstrated that 86% of vaccinated sheep were completely free of viable hydatid cysts when examined approximately 1year after challenge infection. Vaccination reduced the number of viable cysts by 99.3% compared with unvaccinated controls. These results suggest that the EG95 vaccine could have wide applicability as a new tool for use in hydatid control campaigns. Copyright (C) 1999 Australian Society for Parasitology Inc.

Original languageEnglish
Pages (from-to)531-534
Number of pages4
JournalInternational Journal for Parasitology
Volume29
Issue number4
DOIs
Publication statusPublished - 01 Apr 1999

Fingerprint Dive into the research topics of 'Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep'. Together they form a unique fingerprint.

  • Cite this